Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.67
OPK's Cash to Debt is ranked higher than
52% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. OPK: 0.67 )
OPK' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 0.67

Equity to Asset 0.66
OPK's Equity to Asset is ranked higher than
72% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OPK: 0.66 )
OPK' s 10-Year Equity to Asset Range
Min: 0.02   Max: 0.96
Current: 0.66

0.02
0.96
F-Score: 3
Z-Score: 8.10
M-Score: -2.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -160.02
OPK's Operating margin (%) is ranked higher than
67% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. OPK: -160.02 )
OPK' s 10-Year Operating margin (%) Range
Min: -31624.44   Max: -39.08
Current: -160.02

-31624.44
-39.08
Net-margin (%) -188.39
OPK's Net-margin (%) is ranked higher than
66% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. OPK: -188.39 )
OPK' s 10-Year Net-margin (%) Range
Min: -44561.54   Max: -4.59
Current: -188.39

-44561.54
-4.59
ROE (%) -19.67
OPK's ROE (%) is ranked higher than
76% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. OPK: -19.67 )
OPK' s 10-Year ROE (%) Range
Min: -3194.35   Max: -1.4
Current: -19.67

-3194.35
-1.4
ROA (%) -12.93
OPK's ROA (%) is ranked higher than
77% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. OPK: -12.93 )
OPK' s 10-Year ROA (%) Range
Min: -1352.71   Max: -0.83
Current: -12.93

-1352.71
-0.83
ROC (Joel Greenblatt) (%) -860.75
OPK's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. OPK: -860.75 )
OPK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -130662.93   Max: -57.21
Current: -860.75

-130662.93
-57.21
Revenue Growth (3Y)(%) 30.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
92% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. OPK: 30.10 )
OPK' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 135.1
Current: 30.1

0
135.1
EBITDA Growth (3Y)(%) 69.40
OPK's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. OPK: 69.40 )
OPK' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -75.7   Max: 171.4
Current: 69.4

-75.7
171.4
EPS Growth (3Y)(%) 139.10
OPK's EPS Growth (3Y)(%) is ranked higher than
100% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. OPK: 139.10 )
OPK' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.4   Max: 152.4
Current: 139.1

-69.4
152.4
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OPK Guru Trades in Q1 2014

Paul Tudor Jones 12,253 sh (New)
George Soros 1,494,800 sh (+76.98%)
Murray Stahl 123,170 sh (+25.93%)
Mario Gabelli 15,000 sh (unchged)
Jana Partners Sold Out
Steven Cohen Sold Out
» More
Q2 2014

OPK Guru Trades in Q2 2014

Paul Tudor Jones 13,145 sh (+7.28%)
Murray Stahl 125,930 sh (+2.24%)
Mario Gabelli 15,000 sh (unchged)
George Soros 235,600 sh (-84.24%)
» More
Q3 2014

OPK Guru Trades in Q3 2014

Murray Stahl 138,935 sh (+10.33%)
George Soros 235,600 sh (unchged)
Paul Tudor Jones Sold Out
Mario Gabelli 11,000 sh (-26.67%)
» More
Q4 2014

OPK Guru Trades in Q4 2014

George Soros 235,600 sh (unchged)
Mario Gabelli 11,000 sh (unchged)
Murray Stahl 125,752 sh (-9.49%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares
OPKO Health (OPK) has come to my attention because I noticed that the chairman and CEO, Dr. Phillip Frost, has been consistently showing up on the list of CEO buys at GuruFocus. As I look back at the history, he has been doing so for years. According to the Form 4 filed with the SEC, his is the beneficial owner of shares in his own name, his trust, and an LLC. Together he is the beneficial owner of 158.71 million out of the 412.91 million shares outstanding, representing about 38 percent of the shares. As of 6/19/14, his position is valued at $1.457 billion. Phillip Frost has had many successful investments in the past, could this be the next one? Read more...
Weekly CEO Buys Highlight: OPK, PAYC, CLMS, WINA, HBAN
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
P/B 7.60
OPK's P/B is ranked higher than
59% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. OPK: 7.60 )
OPK' s 10-Year P/B Range
Min: 3.65   Max: 50.6
Current: 7.6

3.65
50.6
P/S 68.68
OPK's P/S is ranked lower than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. OPK: 68.68 )
OPK' s 10-Year P/S Range
Min: 15.25   Max: 126.5
Current: 68.68

15.25
126.5
Current Ratio 1.72
OPK's Current Ratio is ranked higher than
56% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. OPK: 1.72 )
OPK' s 10-Year Current Ratio Range
Min: 1.22   Max: 42.13
Current: 1.72

1.22
42.13
Quick Ratio 1.52
OPK's Quick Ratio is ranked higher than
58% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. OPK: 1.52 )
OPK' s 10-Year Quick Ratio Range
Min: 1.08   Max: 42.13
Current: 1.52

1.08
42.13
Days Inventory 134.63
OPK's Days Inventory is ranked higher than
86% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPK: 134.63 )
OPK' s 10-Year Days Inventory Range
Min: 131.84   Max: 500.07
Current: 134.63

131.84
500.07
Days Sales Outstanding 79.99
OPK's Days Sales Outstanding is ranked higher than
78% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. OPK: 79.99 )
OPK' s 10-Year Days Sales Outstanding Range
Min: 38.86   Max: 727.85
Current: 79.99

38.86
727.85

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 98.90
OPK's Price/DCF (Projected) is ranked higher than
87% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. OPK: 98.90 )
OPK' s 10-Year Price/DCF (Projected) Range
Min: 8.27   Max: 66.6
Current: 98.9

8.27
66.6
Price/Median PS Value 1.90
OPK's Price/Median PS Value is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. OPK: 1.90 )
OPK' s 10-Year Price/Median PS Value Range
Min: 0.33   Max: 6.55
Current: 1.9

0.33
6.55
Earnings Yield (Greenblatt) -2.20
OPK's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. OPK: -2.20 )
OPK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.9   Max: 0
Current: -2.2

-2.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Mexico,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, GRIF, BXMT, OPK, RHP Apr 26 2015 
Weekly CEO Buys Highlight: NRZ, BH, OPK, DRI, CLMS Apr 17 2015 
Weekly CEO Buys Highlight: PHII, RHP, OPK, VNR, LUB Apr 02 2015 
Weekly CEO Buys Highlight: S, OPK, CAPL, CLF, MOSY Mar 09 2015 
Recent Stocks Impacted By Insider Buying Feb 21 2015 
Weekly CEO Buys Highlight: HES, GDOT, BH, CUBI, OPK Feb 09 2015 
Weekly CEO Buys Highlight: OPK, TCBI, SWN, EGBN, AZZ Jan 28 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, GPC, CPRX Jan 18 2015 
Weekly CEO Buys Highlight: BH, CLMS, OPK, CPRX, BRT Jan 12 2015 
Weekly CEO Buys Highlight: LTRPA, ENH, BH, OPK, CPTA Dec 28 2014 

More From Other Websites
5 Stocks With Big Insider Buying Apr 22 2015
Lions Gate, Coty And Other Stocks Insiders Have Been Buying Apr 21 2015
OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test Apr 21 2015
OPKO Announces Publication of ProtecT Study Using Kallikrein Biomarkers in 4Kscore Test Apr 21 2015
MabVax Therapeutics Catches Eye of Billionaire Investor Dr. Phillip Frost and OPKO Health Apr 08 2015
MabVax Therapeutics Announces Closing of Financing Apr 06 2015
OPKO HEALTH, INC. Files SEC form 8-K, Other Events Apr 02 2015
Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes Apr 01 2015
Conversion Right Triggered on OPKO 3.0% Convertible Senior Notes Apr 01 2015
OPKO HEALTH, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities Mar 30 2015
Phase 3 Data Supporting Rayaldee™ As a Treatment for Secondary Hyperparathyroidism in Chronic... Mar 27 2015
Opko Health Inc. (OPK), Pacific DataVision, Inc. (PDVW), LGI Homes Inc (LGIH): Three Stocks with... Mar 23 2015
OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources Mar 23 2015
OPKO Investee SciVac Ltd. Enters into Transaction with Levon Resources Mar 23 2015
OPKO HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 19 2015
OPKO Lab Receives Accreditation From College of American Pathologists Mar 18 2015
OPKO Lab Receives Accreditation From College of American Pathologists Mar 18 2015
Cocrystal Pharma to Appoint Jeffrey Meckler as Interim Chief Executive Officer Mar 12 2015
OPKO HEALTH, INC. Financials Mar 06 2015
Phase 3 Data Supporting Rayaldee As a Treatment for Secondary Hyperparathyroidism in Chronic Kidney... Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK